Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $100000.0.

  • UroGen Pharma's Depreciation & Amortization (CF) changed 0.0% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $329000.0, marking a year-over-year decrease of 3586.74%. This contributed to the annual value of $329000.0 for FY2024, which is 5897.76% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Depreciation & Amortization (CF) is $100000.0, which was down 0.0% from $100000.0 recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Depreciation & Amortization (CF) peaked at $224000.0 during Q4 2022, and registered a low of $29000.0 during Q4 2024.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $200000.0 (2021), whereas its average is $163736.8.
  • Per our database at Business Quant, UroGen Pharma's Depreciation & Amortization (CF) soared by 14390.24% in 2021 and then crashed by 8473.68% in 2024.
  • UroGen Pharma's Depreciation & Amortization (CF) (Quarter) stood at $213000.0 in 2021, then increased by 5.16% to $224000.0 in 2022, then fell by 15.18% to $190000.0 in 2023, then plummeted by 84.74% to $29000.0 in 2024, then soared by 244.83% to $100000.0 in 2025.
  • Its last three reported values are $100000.0 in Q3 2025, $100000.0 for Q2 2025, and $100000.0 during Q1 2025.